Sir,

Uraemic pruritus, now better known as chronic kidney disease-related pruritus (CKD-rP), is still a commonly experienced, tormenting and challenging symptom in patients with chronic kidney diseases \[[@R1]\].

There has been an ongoing discussion whether pruritus in chronic kidney disease is brought about by the common disturbance of calcium/phosphate homeostasis \[[@R2]\].

Recently it has been proposed that a vicious circle of metabolic derangements (malnourishment, inflammation, arteriosclerosis) may explain the exaggerated morbidity and mortality in a subset of haemodialysis patients \[[@R3]\]. Inflammation might be the most deleterious factor in this respect which, besides other factors, is related to the occurrence of CKD-rP and down-regulation of fetuin-A, an important calcium-binding circulating protein favouring tissue-calcifications in these patients \[[@R4]\].

Thus, we were interested in whether patients with CKD-rP display lower levels of serum fetuin-A.

Ten patients in a hospital-based haemodialysis centre complaining about CKD-rP were compared to another 12 patients who did not report to have suffered from CKD-rP at least 6 months prior to the interview. Patients with CKD-rP were asked to score the intensity of current pruritus using a visual analogue scale (VAS) ranging from 0 to 10. In both groups, 10 ml of blood was taken immediately after puncture of the arterio-venous fistula, and fetuin-A, 25-hydroxyvitamin D~3~ (25\[OH\]D~3~), total protein, albumin, calcium (corrected for serum albumin), phosphate, and high-sensitivity CRP (hsCRP) were measured.

Independent *t*-tests (continuous variables) and a χ^2^-test (gender) evaluated whether there were significant (*P* \< 0.05) differences between patients with and without CKD-rP.

The mean pruritus intensity of patients with CKD-rP was 5.9 ± 1.9. After identifying one univariate outlier (hsCKP = 35.6) in the group of patients without CKD-rP, CRP was significantly higher in patients with CKD-rP. We failed, however, to find significant differences in serum-calcium, phosphate, fetuin A and 25-OH-Vitamin D3 between the two groups (Table [1](#T1){ref-type="table"}). Additionally, there was no relationship between the intensity of CKD-rP and the metabolic factors measured (including CRP) in patients suffering from pruritus.

###### 

Patient and clinical characteristics between the two groups. PTH (intact parathyreoid hormone), hsCRP (high-sensitivity C-reactive protein), 25(OH)D~3~ (25-hydroxyvitamin D~3~)

                              CKD-rP          No CKD-rP       
  --------------------------- --------------- --------------- ------
  Kt/V                        1.5 (0.40)      1.3 (0.28)      0.28
  Age                         66.2 (12.7)     66.5 (13.9)     0.48
  Male \[*n* (%)\]            5 (50.0)        8 (72.7)        0.39
  Female \[*n* (%)\]          5 (50.0)        3 (27.3)        
  Time on haemodialysis                                       
  in months                   40.6 (30.5)     38.7 (50.1)     0.92
  Current use of                                              
  1-OH-vitamin D              0.5 (0.5)       0.7 (0.5)       0.31
  Current use of cinacalcet   0.3 (0.5)       0.5 (0.5)       0.28
  PTH (ng/L)                  317.5 (334.0)   525.8 (474.3)   0.26
  Fetuin A (g/L)              0.4 (0.1)       0.4 (0.1)       0.53
  Corrected calcium           2.3 (0.2)       2.2 (0.2)       0.45
  Calcium (mmol/L)            2.2 (0.2)       2.2 (0.2)       0.48
  Protein (g/L)               69.3 (4.7)      68.4 (4.5)      0.65
  Albumin (g/L)               35.7 (3.3)      35.7 (5.9)      0.99
  HsCRP (mg/L)                12.5 (9.8)      4.1 (3.0)       0.02
  25(OH)D~3~ (μg/L)           13.9 (4.0)      14.2 (6.3)      0.91
  Phosphate (mmol/L)          1.8 (0.6)       1.8 (0.4)       0.73

Although our study approach has methodological limitations (small number of patients, no matched pairs) the results suggest that neither calcium-binding protein fetuin-A levels nor 25(OH)D~3~ values were noticeably different in patients with CKD-rP compared to patients without CKD-rP. On the other hand, the marker for inflammation, CRP, was found to be significantly higher in patients with CKD-rP as shown before \[[@R5]\]. We hence believe that other inflammation-driven processes need to be studied in the future in order to understand the pathomechanisms of CKD-rP.
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